Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Bramlage

Showing results (61-70 of 429) with videos related to

Pageof 43
Sort By:
Expert Opinion on Pharmacotherapy|June 24, 2008
Quality of life in hypertension management using olmesartan in primary careAndré C Schmidt, Peter Bramlage, Roger Limberg, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|July 4, 2014
Clinical significance of conduction disturbances after aortic valve intervention: current evidenceManuel Martinez-Selles, Peter Bramlage, Martin Thoenes, et al.
Interactive Cardiovascular and Thoracic Surgery|May 29, 2019
Minimizing the risk for left ventricular rupture during transcatheter aortic valve implantation by reducing the presence of stiff guidewires in the ventricleNiels Erik Nielsen, Julia Baranowska, Peter Bramlage, et al.
Diabetes & Vascular Disease Research|November 15, 2015
Incidence, characteristics and impact of hypoglycaemia in patients receiving intensified treatment for inadequately controlled type 2 diabetes mellitusDiethelm Tschöpe, Peter Bramlage, Steffen Schneider, et al.
Vascular Health and Risk Management|December 11, 2008
Effects of the vasodilating beta-blocker nebivolol on smoking-induced endothelial dysfunction in young healthy volunteersAndré C Schmidt, Burkhard Flick, Elke Jahn, et al.
Cardiovascular Diabetology|February 4, 2015
A real world comparison of sulfonylurea and insulin vs. incretin-based treatments in patients not controlled on prior metformin monotherapyAnselm K Gitt, Peter Bramlage, Steffen Schneider, et al.
Vascular Health and Risk Management|June 23, 2007
Role of the vasodilator peptide angiotensin-(1-7) in cardiovascular drug therapyChristoph Schindler, Peter Bramlage, Wilhelm Kirch, et al.
Respiration; International Review of Thoracic Diseases|December 5, 2014
Current perspectives on the contribution of inhaled corticosteroids to an increased risk for diabetes onset and progression in patients with chronic obstructive pulmonary diseaseFelix J F Herth, Peter Bramlage, Dirk Müller-Wieland
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|February 5, 2021
Effectiveness and Safety of Switching Rapid-Acting Insulins to Insulin Glulisine in Patients with Diabetes: The Observational IGLU-S StudyJochen Seufert, Martin Pfohl, Anja Borck, et al.
Cancer Chemotherapy and Pharmacology|May 13, 2015
Targeted therapies for treatment of renal cell carcinoma: recent advances and future perspectivesJoan Minguet, Katherine H Smith, Carsten P Bramlage, et al.
Pageof 43

Showing results (61-70 of 429) with videos related to

Sort By:
Pageof 43
Expert Opinion on Pharmacotherapy|June 24, 2008
Quality of life in hypertension management using olmesartan in primary careAndré C Schmidt, Peter Bramlage, Roger Limberg, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|July 4, 2014
Clinical significance of conduction disturbances after aortic valve intervention: current evidenceManuel Martinez-Selles, Peter Bramlage, Martin Thoenes, et al.
Interactive Cardiovascular and Thoracic Surgery|May 29, 2019
Minimizing the risk for left ventricular rupture during transcatheter aortic valve implantation by reducing the presence of stiff guidewires in the ventricleNiels Erik Nielsen, Julia Baranowska, Peter Bramlage, et al.
Diabetes & Vascular Disease Research|November 15, 2015
Incidence, characteristics and impact of hypoglycaemia in patients receiving intensified treatment for inadequately controlled type 2 diabetes mellitusDiethelm Tschöpe, Peter Bramlage, Steffen Schneider, et al.
Vascular Health and Risk Management|December 11, 2008
Effects of the vasodilating beta-blocker nebivolol on smoking-induced endothelial dysfunction in young healthy volunteersAndré C Schmidt, Burkhard Flick, Elke Jahn, et al.
Cardiovascular Diabetology|February 4, 2015
A real world comparison of sulfonylurea and insulin vs. incretin-based treatments in patients not controlled on prior metformin monotherapyAnselm K Gitt, Peter Bramlage, Steffen Schneider, et al.
Vascular Health and Risk Management|June 23, 2007
Role of the vasodilator peptide angiotensin-(1-7) in cardiovascular drug therapyChristoph Schindler, Peter Bramlage, Wilhelm Kirch, et al.
Respiration; International Review of Thoracic Diseases|December 5, 2014
Current perspectives on the contribution of inhaled corticosteroids to an increased risk for diabetes onset and progression in patients with chronic obstructive pulmonary diseaseFelix J F Herth, Peter Bramlage, Dirk Müller-Wieland
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|February 5, 2021
Effectiveness and Safety of Switching Rapid-Acting Insulins to Insulin Glulisine in Patients with Diabetes: The Observational IGLU-S StudyJochen Seufert, Martin Pfohl, Anja Borck, et al.
Cancer Chemotherapy and Pharmacology|May 13, 2015
Targeted therapies for treatment of renal cell carcinoma: recent advances and future perspectivesJoan Minguet, Katherine H Smith, Carsten P Bramlage, et al.
Pageof 43